Is Protagenic Therapeutics (PTIX) Poised for a Breakthrough in Neuropsychiatric Treatment

Related Articles

Is EcoSolutions Waste Poised for a Biofuel Breakthrough

3 months ago

Is Arcturus Therapeutics Poised for a Massive Upside in 2026

3 months ago

Is TeraDrill (TDRL) Poised for a Breakthrough in Mining Automation

1 months ago

Is BioVie's Bezisterim Poised for a Breakthrough in Neurodegenerative Diseases

3 weeks ago

Category

You may also like

Stock News•2 weeks ago

Axsome Therapeutics Readies Auvelity Alzheimer's Agitation Launch, Expands CNS Pipeline

Axsome Therapeutics is launching Auvelity for Alzheimer's disease agitation this month, while expanding its use in major depressive disorder and advancing its CNS pipeline.

CNS

Share

Stock News•3 weeks ago

The Next Great AI Revolution May Be Drug Delivery

NeOnc (NASDAQ:NTHI) is advancing proprietary drug delivery technologies and therapies specifically targeting aggressive brain cancers and CNS-related conditions. The company aims to address significan...

NTHI

Share

Stock News•1 months ago

Protagenic Therapeutics Engages Floyd Regulatory Strategic Consulting as Regulatory Affairs Advisor and Danforth Health as Strategic Operations Partner

Protagenic Therapeutics (OTCQB:PTIX) engaged Floyd Regulatory Strategic Consulting and Danforth Health to support the clinical development of its lead candidate, PT00114. These partnerships aim to acc...

PTIX

Share

Stock News•1 months ago

Silo Pharma Files Provisional Patent for Ibogaine-Based Therapeutic Targeting Traumatic Brain Injury

Silo Pharma filed a provisional patent for an ibogaine-based therapeutic targeting traumatic brain injury. This initiative aligns with federal efforts to accelerate mental health innovation through th...

SILO

Share